Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH MATH 2020 | Prevention of acute GvHD

Florent Malard • 8 Jun 2020
IACH MATH 2020
General Anti-thymocyte globulin Cyclophosphamide

Florent Malard, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the progress in graft-versus-host disease (GvHD) prophylaxis containing either post-transplant cyclophosphamide or anti-thymocyte globulin (ATG). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Florent Malard

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:44
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard • 11 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:04
Retrospective study on the outcomes of patients with myeloma treated with cilta-cel and ide-cel
Florent Malard • 20 May 2023

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals